4 news items
Gossamer Bio Secures $160M Partnership with Chiesi Group to Accelerate Development of Pulmonary Hypertension Treatment, $486M Potential for Seralutinib Collaboration
GOSS
6 May 24
to develop and bring this therapy to patients world-wide," said Giuseppe Accogli, Group CEO of Chiesi. "Gossamer shares Chiesi's commitment
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
, Group CEO of Chiesi. "Gossamer shares Chiesi's commitment to using innovation to promote the health and well-being of people around the world and we
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
GOSS
3 May 24
in Lancet Respiratory Medicine represents a significant milestone in our ongoing commitment to addressing unmet medical needs for patients
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
GOSS
12 Mar 24
Gossamer's commitment to addressing rare forms of pulmonary hypertension, or PH.
Ms. Drynan joins
- Prev
- 1
- Next